Join
Live feed
·
PRReleasevia Quantisnow
Akari Therapeutics plc logo

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKTX (Akari Therapeutics plc) and more on Quantisnow.